Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
about
Proliferation and differentiation potential of CD133+ and CD34+ populations from the bone marrow and mobilized peripheral blood.Optimizing Stem Cells Mobilization Strategies to Ameliorate Patient Outcomes: A Review of Guide- lines and Recommendations.Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.The evolving role of plerixafor in hematopoietic progenitor cell mobilization.The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies.Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma.Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance.Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose.Lymphocyte recovery and infused CD34+ cells dose: Effect on the evolution after stem cell autotransplantation.Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo OsseoEngraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.Autologous peripheral blood hematopoietic cell transplantation in dogs with B-cell lymphoma.Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation.Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma.
P2860
Q30484652-E6F62516-9832-4E75-BDC0-E16E69E0E688Q37682128-0DC17475-12AE-449E-BA0D-6DEEC1DFCA1FQ37827058-5111633C-C6B7-4CBD-BFBF-2B53A68B5757Q38077807-09B48973-858E-4BD0-A2AD-022C167F88FFQ38256923-95A109B8-37C4-48ED-B41A-D24FBE6A8DF2Q39777744-750289B0-E9C6-4F8B-AB4C-00D8B7EFC14EQ40111616-61101C07-9448-4AB9-83C2-8DCC01D58B17Q40328857-8DAEA2EA-3B19-40EA-A056-93EC0EEC94EEQ40563007-03B70B15-109F-4748-9B0E-C136F73F9090Q41893175-52D152AD-1842-4C54-9AF6-9DE46EBDC280Q42592824-DB93189E-0DC6-421D-A46B-064C431E0E06Q43524297-E7BF4F8F-D25D-4F74-B82C-2412F2EFA832Q44865416-04FB5AB1-0EB3-4689-A860-374FE7DCF475Q50073302-94C81D73-D663-467A-AF86-29359F929C4FQ52859049-2982BE18-9C45-4DAB-8797-F0CD3454EF90
P2860
Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Higher infused CD34+ hematopoi ...... ion in non-Hodgkin's lymphoma.
@en
Higher infused CD34+ hematopoi ...... ion in non-Hodgkin's lymphoma.
@nl
type
label
Higher infused CD34+ hematopoi ...... ion in non-Hodgkin's lymphoma.
@en
Higher infused CD34+ hematopoi ...... ion in non-Hodgkin's lymphoma.
@nl
prefLabel
Higher infused CD34+ hematopoi ...... ion in non-Hodgkin's lymphoma.
@en
Higher infused CD34+ hematopoi ...... ion in non-Hodgkin's lymphoma.
@nl
P2093
P2860
P1433
P1476
Higher infused CD34+ hematopoi ...... ion in non-Hodgkin's lymphoma.
@en
P2093
Byeong Seok Sohn
Byung Woog Kang
Chan-Jeoung Park
Cheolwon Suh
Dae Ho Lee
Dok Hyun Yoon
Eun Kyoung Kim
Geundoo Jang
Jeong-Eun Kim
P2860
P304
P356
10.1111/J.1537-2995.2009.02202.X
P577
2009-05-11T00:00:00Z